Loading…
Bolt Biotherapeutics, Inc. is projected to rise to $4.18 by 2027, a +5% move from its current price of $3.98. BOLT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.84 | $3.98 | $4.12 | +0.02% |
| Aug 6 | $3.79 | $3.98 | $4.18 | +0.04% |
| Aug 7 | $3.75 | $3.98 | $4.23 | +0.06% |
| Aug 8 | $3.72 | $3.98 | $4.27 | +0.08% |
| Aug 9 | $3.69 | $3.98 | $4.31 | +0.10% |
| Aug 10 | $3.66 | $3.98 | $4.34 | +0.12% |
| Aug 11 | $3.64 | $3.99 | $4.37 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.64 | $3.99 | $4.37 | +0.14% |
| Week 2 | $3.50 | $3.99 | $4.55 | +0.28% |
| Week 3 | $3.41 | $4.00 | $4.69 | +0.42% |
| Week 4 | $3.33 | $4.00 | $4.81 | +0.56% |
| Week 5 | $3.26 | $4.01 | $4.92 | +0.71% |
| Week 6 | $3.20 | $4.01 | $5.03 | +0.85% |
| Week 7 | $3.15 | $4.02 | $5.13 | +0.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc.
in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. It trades at $3.81 per share and has a market capitalization of $7.32M, with a market rank of 5087.
The current price and near-term forecast place the stock near the low-to-mid $3 range. The 30-day forecast for 2026 shows an average of $3.81, a low of $3.78, and a high of $5.15, with neutral sentiment.
In the longer horizon, the forecast envisions growing upside with 2029-2035 forecasts showing averages from $5.68 to $8.23 and ROIs from 40.7% to 116%, and 2040 and 2050 producing averages of $8.78 and $19.60 with ROIs of 130.5% and 414.3%, respectively, all with bullish sentiment in those years.
A major floor 14.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.0% below — buyers have tended to step in here.
The nearest ceiling, 12.4% above — a clean break opens room to run.
A major ceiling 35.4% above — clearing it would confirm fresh momentum.
Key BOLT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BOLT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.94 | Buy | $3.95 | Buy |
| MA 10 | $3.99 | Sell | $3.98 | Buy |
| MA 20 | $4.02 | Sell | $4.04 | Sell |
| MA 50 | $4.34 | Sell | $4.25 | Sell |
| MA 100 | $4.49 | Sell | $4.50 | Sell |
| MA 200 | $4.95 | Sell | $5.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.03 | Neutral |
| Stoch RSI (14) | 37.97 | Neutral |
| CCI (20) | -16.38 | Neutral |
| Williams %R (14) | -72.93 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -5.23 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 27.07 | Neutral |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 47.84 | Neutral |
| Momentum (10) | -0.43 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 3.91 | Buy |
| ADX (14) | 12.97 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture for BOLT is NEUTRAL. RSI14 is 40, and the price is hovering relative to the SMA50 at $4.44 and the SMA200 at $5.01. Nearby support is at $3.78 and resistance at $4.77, framing a 30-day range of $2.95 to $4.93.
The near-term setup shows elevated volatility, with annualized volatility listed at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.78 | $3.98 | $5.20 | 0% | Neutral | |
| $3.25 | $4.18 | $5.73 | +5% | Neutral | |
| $3.23 | $4.32 | $6.19 | +8% | Neutral | |
| $4.11 | $5.65 | $8.41 | +42% | Bullish | |
| $4.25 | $6.01 | $9.21 | +51% | Bullish | |
| $4.17 | $6.05 | $9.51 | +52% | Bullish | |
| $4.09 | $6.08 | $9.78 | +53% | Bullish | |
| $3.73 | $5.67 | $9.31 | +42% | Bullish | |
| $4.17 | $6.47 | $10.83 | +63% | Bullish | |
| $5.11 | $8.09 | $13.79 | +103% | Bullish | |
| $5.18 | $9.00 | $16.50 | +126% | Bullish | |
| $9.43 | $19.38 | $39.46 | +387% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.78 | $3.98 | $4.79 | +0.00% |
| September 2026 | $3.44 | $4.10 | $5.05 | +3.04% |
| October 2026 | $3.37 | $4.05 | $5.06 | -1.16% |
| November 2026 | $3.26 | $3.94 | $4.97 | -2.71% |
| December 2026 | $3.35 | $4.08 | $5.20 | +3.49% |
Click any year to see its month-by-month BOLT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BOLT price prediction for 2026 points to an average of $3.98 (low $3.78, high $5.20) — a potential gain of 0% on today's $3.98. Price action looks broadly range-bound.
In 2027, BOLT is projected to trade between $3.25 and $5.73, averaging $4.18 — a potential gain of +5% from today's $3.98. That is up +5% on the projected 2026 average. A consolidation phase looks the most probable path here.
Bolt Biotherapeutics, Inc.'s 2028 outlook centres on $4.32, within a $3.23 to $6.19 range. That is up +3% on the projected 2027 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2029, BOLT could reach as high as $8.41, with a base case around $5.65 and support toward $4.11 — roughly +42% from $3.98. Buyers look set to stay in control over this stretch.
Expect BOLT to range from $4.25 to $9.21 through 2030. The $6.01 average target implies a +51% move from current prices. That is up +6% on the projected 2029 average. Momentum favours further upside here.
The BOLT price prediction for 2031 points to an average of $6.05 (low $4.17, high $9.51) — a potential gain of +52% on today's $3.98. Buyers look set to stay in control over this stretch.
In 2032, BOLT is projected to trade between $4.09 and $9.78, averaging $6.08 — a potential gain of +53% from today's $3.98. That is up 0% on the projected 2031 average. Momentum favours further upside here.
Bolt Biotherapeutics, Inc.'s 2033 outlook centres on $5.67, within a $3.73 to $9.31 range. That is -7% versus the projected 2032 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BOLT could reach as high as $10.83, with a base case around $6.47 and support toward $4.17 — roughly +63% from $3.98. Momentum favours further upside here.
Expect BOLT to range from $5.11 to $13.79 through 2035. The $8.09 average target implies a +103% move from current prices. That is up +25% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BOLT price prediction for 2040 points to an average of $9.00 (low $5.18, high $16.50) — a potential gain of +126% on today's $3.98. Momentum favours further upside here.
In 2050, BOLT is projected to trade between $9.43 and $39.46, averaging $19.38 — a potential gain of +387% from today's $3.98. That is up +115% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BOLT today (≈ 251.256281 BOLT) could be worth
$4,869.22
+$3,869.22 (+387%) by 2050 · US Dollar
Based on the average projected BOLT price of $19.38 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BOLTwould be worth at today's price.
$1,000 invested in BOLT on Jul 31, 2025 (≈ 176.991147 BOLT) would be worth
$704.42
-$295.58 (-29.6%) today · 0.70× · US Dollar
Based on a BOLT entry price of $5.65 vs. today's $3.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.83 | $1,039.16 | +3.9% |
| 1 month ago | $3.99 | $997.49 | -0.3% |
| 3 months ago | $5.06 | $786.56 | -21.3% |
| 6 months ago | $5.91 | $673.43 | -32.7% |
| 1 year ago | $5.65 | $704.42 | -29.6% |
| All time (5.0y) ago | $274 | $14.53 | -98.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BOLT forecast.
Our base-case forecast reaches $8.00 around 2035.
Implied market cap at $8.00: $15.37M
The multi-year forecast starts with a neutral stance in 2026, with min $3.78, avg $3.81, max $5.15 and ROI 0%, signaling little expected movement that year.
In 2027 the forecast shows min $3.04, avg $3.96, max $5.55, with ROI 4.1% and neutral sentiment. In 2028 the min is $3.02, the avg is $4.12, the max is $6.06, with ROI 8.1% and neutral sentiment.
From 2029 onward the outlook turns bullish, with 2029 min $4.02, avg $5.68, max $8.69 and ROI 49.1; 2030 min $4.05, avg $5.90, max $9.31 and ROI 54.8; 2031 min $3.92, avg $5.87, max $9.54 and ROI 54.1; 2032 min $3.89, avg $6.00, max $9.98 and ROI 57.4; 2033 min $3.39, avg $5.36, max $9.12 and ROI 40.7; 2034 min $3.92, avg $6.35, max $11.03 and ROI 66.5; 2035 min $4.96, avg $8.23, max $14.58 and ROI 116; 2040 min $4.74, avg $8.78, max $16.83 and ROI 130.5; 2050 min $8.82, avg $19.60, max $42.00 and ROI 414.3. The sentiment is bullish in these years.
These figures are forecasts and not guarantees; actual results may differ and investments carry risk.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $5.90 with a max of $9.31 and a min of $4.05, and a forecast ROI of 54.8% with bullish sentiment.
Forecasts show neutral sentiment in 2026 and bullish sentiment from 2029 onward, with a forecast ROI of 54.8% by 2030 and up to 414.3% by 2050; these are estimates and not guarantees.
Yes. The forecasted max prices reach above $9.31 in 2030, $11.03 in 2034, and $14.58 in 2035, indicating potential to exceed $10 in those years.
Current price: $3.81. Market cap: $7.32M. Rank: 5087.
RSI14 is 40. SMA50 is $4.44 and SMA200 is $5.01. Support is at $3.78 and resistance at $4.77. The 30-day range is $2.95 to $4.93, with neutral sentiment and annualized volatility at 70%.
Bolt Biotherapeutics, Inc. Community Discussion
0Share your Bolt Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.